Voloridge Investment Management LLC Buys 201,003 Shares of Certara, Inc. (NASDAQ:CERT)

Voloridge Investment Management LLC increased its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 269.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 275,633 shares of the company's stock after purchasing an additional 201,003 shares during the quarter. Voloridge Investment Management LLC owned approximately 0.17% of Certara worth $2,935,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. ArrowMark Colorado Holdings LLC increased its position in Certara by 164.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock valued at $66,171,000 after acquiring an additional 3,861,674 shares in the last quarter. Ameriprise Financial Inc. increased its position in Certara by 864.0% in the 4th quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock valued at $40,253,000 after acquiring an additional 3,387,590 shares in the last quarter. Brown Brothers Harriman & Co. increased its position in Certara by 63.8% in the 4th quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock valued at $40,668,000 after acquiring an additional 1,487,998 shares in the last quarter. Bank of New York Mellon Corp increased its position in Certara by 169.0% in the 4th quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock valued at $21,248,000 after acquiring an additional 1,253,385 shares in the last quarter. Finally, ExodusPoint Capital Management LP acquired a new stake in Certara in the 4th quarter valued at about $11,542,000. Institutional investors and hedge funds own 73.96% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on CERT shares. Robert W. Baird raised their price objective on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. TD Cowen began coverage on shares of Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price on the stock. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Stephens reaffirmed an "overweight" rating and issued a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. Finally, Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $15.67.

Certara Trading Down 0.1%

Certara stock traded down $0.01 during midday trading on Friday, hitting $11.39. 987,275 shares of the stock were exchanged, compared to its average volume of 1,342,245. The company has a fifty day simple moving average of $11.86 and a two-hundred day simple moving average of $11.80. Certara, Inc. has a 52 week low of $8.64 and a 52 week high of $17.76. The stock has a market capitalization of $1.85 billion, a PE ratio of -56.95, a P/E/G ratio of 9.29 and a beta of 1.57. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.04. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. During the same quarter last year, the firm earned $0.10 EPS. Certara's quarterly revenue was up 9.7% compared to the same quarter last year. Equities research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current fiscal year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.